Efficacy of GONB in Patients of Migraine

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Inclusion Criteria:Patients between 18 to 60 yearsdiagnosed case of migraineExclusion Criteria:Patients with known allergies to local anaestheticspregnancyhistory of cranial or cervical surgeryhead injuryheadaches secondary to medication overusepatients with uncontrolled systemic disease like blood pressure, diabetes mellitushypo or hyperthyroidismpatient who had already received GONB or botulinum toxin type A therapy within last 6 monthsmajor psychiatric disorderhistory of chronic pain syndromes